高级检索
蔡青青, 程蕾蕾. 免疫检查点抑制剂相关心脏毒性[J]. 中国临床医学. DOI: 10.12025/j.issn.1008-6358.2024.20240486
引用本文: 蔡青青, 程蕾蕾. 免疫检查点抑制剂相关心脏毒性[J]. 中国临床医学. DOI: 10.12025/j.issn.1008-6358.2024.20240486
Qingqing cai, Leilei Cheng. Immune checkpoint inhibitors induced cardiotoxicity[J]. Chinese Journal of Clinical Medicine. DOI: 10.12025/j.issn.1008-6358.2024.20240486
Citation: Qingqing cai, Leilei Cheng. Immune checkpoint inhibitors induced cardiotoxicity[J]. Chinese Journal of Clinical Medicine. DOI: 10.12025/j.issn.1008-6358.2024.20240486

免疫检查点抑制剂相关心脏毒性

Immune checkpoint inhibitors induced cardiotoxicity

  • 摘要: 免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs)是近年来出现的一种新型肿瘤免疫治疗药物,已广泛应用于多种恶性肿瘤的治疗。但免疫系统的过度激活也会诱发免疫相关不良事件,其中ICIs诱发的心脏毒性包括心肌炎、心包疾病、动脉粥样硬化等。ICIs相关心脏毒性虽然发生率不高,但可能导致严重的临床症状,甚至死亡。因此,临床工作中需及时识别和管理ICIs相关心脏毒性,一旦确诊,需根据疾病的严重程度及时进行治疗。ICIs相关心脏毒性的规范化防治需要多学科共同协作,为患者提供全周期个体化监测与管理。

     

    Abstract: Immune checkpoint inhibitors (ICIs) have emerged as one of the novel immunotherapy drugs in recent years, and been approved for the treatment of multiple different tumour types. However, overactication of the immune system may lead to immune-related advese events, among these, ICIs-induced cardiotoxicity include myocarditis, pericardial disease and atherosclerosis. Although the incidence of ICIs-induced cardiotoxicity is rare, it may lead to serious clinical complications and even death. Thus, timely identification and management of ICIs-induced cardiotoxicity is vital in clinical practice. Once diagnosed, prompt treatment is required accroading to the severity of the disease. Standardized prevention and treatment strategies need multidisciplinary collaboration to provide long-term individualized monitoring and management to patients.

     

/

返回文章
返回